Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
04 Outubro 2023 - 5:05PM
Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology
company developing medicines for broad populations of cancer
patients with an initial aim to develop a universal-RAS therapy,
today announced that it will present preclinical data on IMM-1-104,
its lead clinical-stage program, and IMM-6-415 at the
AACR-NCI-EORTC International Conference on Molecular Targets and
Cancer Therapeutics, being held October 11-15, 2023 in Boston.
Details for the poster presentations are as follows:
Title: Predicting activity of IMM-1-104
as single agent and in combination for patients with RAS or RAF
mutant tumorsDate: Thursday, October 12,
2023, 12:30 p.m. - 4:00 p.m. ETPoster session:
Poster Session ALocation: Level 2, Exhibit Hall
DAbstract number: A134
Title: Deep Cyclic Inhibition of the
MAPK pathway with IMM-6-415, alone and in combination with
encorafenib, demonstrates anti-tumor activity and tolerability in
RAF mutant tumors in
vivoDate: Thursday, October 12, 2023,
12:30 p.m. - 4:00 p.m. ETPoster session: Poster
Session ALocation: Level 2, Exhibit Hall
DAbstract number: A093
The abstracts will be available on the AACR-NCI-EORTC
International Conference on Molecular Targets and Cancer
Therapeutics website. Following presentation, the posters will be
available on the publications section of Immuneering’s website at
https://immuneering.com/publications.
About IMM-1-104
IMM-1-104 aims to achieve universal-RAS activity that
selectively impacts cancer cells to a greater extent than healthy
cells, through deep cyclic inhibition of the MAPK pathway with
once-daily oral dosing. IMM-1-104 is currently being evaluated in a
Phase 1/2a study in patients with advanced solid tumors harboring
RAS mutations for whom there are limited treatment options
(NCT05585320).
About IMM-6-415
IMM-6-415 targets RAF and RAS mutant tumors through deep cyclic
inhibition of the MAPK pathway with an accelerated cadence.
IMM-6-415 was designed with unique drug-like properties that
distinguish it from other programs in the Immuneering pipeline,
including a shorter half-life than IMM-1-104 which gives IMM-6-415
an accelerated cadence relative to the once-daily dosing of
IMM-1-104. IMM-6-415 is being developed for monotherapy and
combination applications in oncology, including the ability to
enhance immune mediated therapy in certain settings. IND filing for
IMM-6-415 is expected in the fourth quarter of 2023.
About Immuneering Corporation
Immuneering is a clinical-stage oncology company developing
medicines for broad populations of cancer patients with an initial
aim to develop a universal-RAS therapy. The Company aims to achieve
universal activity through deep cyclic inhibition of the MAPK
pathway, impacting cancer cells while sparing healthy cells.
Immuneering’s lead product candidate, IMM-1-104, is in a Phase 1/2a
study in patients with advanced solid tumors harboring RAS
mutations. The company’s development pipeline also includes
IMM-6-415, a universal-MAPK program, as well as several early-stage
programs. For more information, please visit
www.immuneering.com.
Forward-Looking Statements
This press release contains "forward-looking statements"
including, without limitation, statements regarding Immuneering’s
expectations regarding the treatment potential of IMM-1-104 and
IMM-6-415; the design, enrollment criteria and conduct of the Phase
1/2a clinical trial of IMM-1-104 in patients with advanced solid
tumors; the timing of additional trial updates, including
recommended phase 2 dose and additional safety and activity data;
the timing of submission of the IND for IMM-6-415; and
Immuneering’s ability to advance its pipeline and further diversify
its portfolio and make progress towards its longstanding goal of
creating better medicines for cancer patients. Forward-looking
statements are based on Immuneering’s current expectations and are
subject to inherent uncertainties, risks and assumptions that are
difficult to predict. Factors that could cause actual results to
differ include, but are not limited to, the risks inherent in
oncology drug research and development, including target discovery,
target validation, lead compound identification, lead compound
optimization, preclinical studies, and clinical trials. These and
other risks and uncertainties are described more fully in the
section titled "Risk Factors" in Immuneering’s most recent Form
10-Q filed with the U.S. Securities and Exchange Commission.
Forward-looking statements contained in this announcement are made
as of this date, and Immuneering undertakes no duty to update such
information except as required under applicable law.
Media Contact:Gina Nugent Nugent Communications
617-460-3579 gina@nugentcommunications.com
Investor Contacts: Laurence Watts Gilmartin
Group 619-916-7620 laurence@gilmartinir.com
or
Kiki Patel, PharmD Gilmartin Group
332-895-3225kiki@gilmartinir.com
Immuneering (NASDAQ:IMRX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Immuneering (NASDAQ:IMRX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024